LBL-024 combo for advanced esophageal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer has at least one tumor that can be measured on scans.
- You are healthy enough to be up and about (performance status 0 or 1).
- You have not had other cancer drugs or treatments in the past 4 weeks.
- You do not have active hepatitis B or C, HIV, or an autoimmune disease.
- If you can have children, you agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination drug called LBL-024 in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the treatment can help shrink the tumor or slow the cancer's growth.
This trial tests a new drug combination for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if adding LBL-024 to other treatments can help shrink tumors or slow their growth.
This trial tests a new drug combination (LBL-024) for people with advanced solid tumors, including bile duct and liver cancers. It aims to see if the treatment is safe and effective for those who have not responded to other therapies.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
This trial tests a new drug (LBL-024) combined with standard chemo as a first treatment for a rare and fast-growing neuroendocrine cancer (EP-NEC) that started outside the lungs. It may offer a new option for people whose cancer has spread and who haven't had treatment yet.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
Hear when a new Advanced Solid Tumour trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.